CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

Novo Nordisk's high-dose Wegovy shows 20.7% weight loss in Phase 3 but falls short of Eli Lilly's Zepbound, raising questions ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

FDA approves AstraZeneca's Calquence as first BTK inhibitor for first-line mantle cell lymphoma, leading BeiGene's Brukinsa ...

FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug ...

After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to ...

Teva is the latest drugmaker to file suit against Medicare negotiations. But unlike other companies that have challenged the ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

The EMA's human medicines committee recommended 114 medicines for approval in 2024, marking the highest number of positive ...